Next Article in Journal
Cytokinesis-Block Micronucleus Cytome Assay Evolution into a More Comprehensive Method to Measure Chromosomal Instability
Next Article in Special Issue
Thiopurine Drugs in the Treatment of Ulcerative Colitis: Identification of a Novel Deleterious Mutation in TPMT
Previous Article in Journal
Molecular Evolution of Maize Ascorbate Peroxidase Genes and Their Functional Divergence
Previous Article in Special Issue
Association between the TPMT*3C (rs1142345) Polymorphism and the Risk of Death in the Treatment of Acute Lymphoblastic Leukemia in Children from the Brazilian Amazon Region
Open AccessReview

Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations

Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 Leiden, The Netherlands
*
Author to whom correspondence should be addressed.
Genes 2020, 11(10), 1205; https://doi.org/10.3390/genes11101205
Received: 16 September 2020 / Revised: 10 October 2020 / Accepted: 14 October 2020 / Published: 15 October 2020
Tacrolimus-modified release formulations allow for once-daily dosing, and adherence is better compared to the twice-daily immediate release formulation. When patients are switched from one formulation to another, variable changes in drug concentrations are observed. Current data suggest that the changes in drug exposure are larger in patients who express the CYP3A5 enzyme (CYP3A5 *1/*3 or *1/*1) compared to nonexpressers (CYP3A5*3/*3). Possibly, these differences are due to the fact that in the upper region of the small intestine CYP3A activity is higher, and that this expression of CYP3A decreases towards the more distal parts of the gut. Modified release formulations may therefore be subject to a less presystemic metabolism. However, the full implications of pharmacogenetic variants affecting the expression and function of drug transporters in the gut wall and of enzymes involved in phase I and phase II metabolism on the different formulations are incompletely understood, and additional studies are required. Conclusions: In all patients in whom the formulation of tacrolimus is changed, drug levels need to be checked to avoid clinically relevant under- or overexposure. In patients with the CYP3A5 expresser genotype, this recommendation is even more important, as changes in drug exposure can be expected. View Full-Text
Keywords: tacrolimus; pharmacokinetics; CYP3A; immediate release; modified release; switching; transplantation; therapeutic drug monitoring; pharmacogenetics tacrolimus; pharmacokinetics; CYP3A; immediate release; modified release; switching; transplantation; therapeutic drug monitoring; pharmacogenetics
MDPI and ACS Style

Gelder, T.; Etsouli, O.; Moes, D.J.; Swen, J.J. Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations. Genes 2020, 11, 1205.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop